Biomarkers in the context of managing severe asthma
Journal of Precision Respiratory Medicine · 2019
DOI: 10.2500/jprm.2019.190009 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Precision Respiratory Medicine, 2019. Verfasst von Stanley J. Szefler.
Abstract (Originalsprache)
Only recently have asthma strategies addressed biomarkers in asthma management, for example, as applied in the identification of severe asthmatics likely to respond to biologic therapy. Three biomarkers are readily available for clinical application in managing severe asthma including blood eosinophils, exhaled nitric oxide and serum IgE. While we have a limited number of biomarkers for clinical application, the available biomarkers have ushered in the era of personalized medicine for asthma. These three biomarkers are readily available for application in the clinic setting to select medications and to monitor response to treatment as well as medication adherence. These biomarkers can be used to modify the cost of uncontrolled asthma and also used to select those patients likely to respond to the available biologic therapies for severe asthma.
Zitieren
APA
Szefler, S. J. (2019). Biomarkers in the context of managing severe asthma. Journal of Precision Respiratory Medicine. https://doi.org/10.2500/jprm.2019.190009
Vancouver
Szefler SJ. Biomarkers in the context of managing severe asthma. Journal of Precision Respiratory Medicine. 2019. doi:10.2500/jprm.2019.190009
BibTeX
@article{Szefler2019,
author = {Szefler, Stanley J.},
title = {Biomarkers in the context of managing severe asthma},
journal = {Journal of Precision Respiratory Medicine},
year = {2019},
doi = {10.2500/jprm.2019.190009}
}
EUVIMED